NCT04142164

Brief Summary

Evaluation if a computer-based tutorial ("MacInfo" tool) improves the patients' knowledge about intravitreal drug injections, associated risks, and the underlying diseases of treatment-naive patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 24, 2019

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

October 25, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 29, 2019

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

February 8, 2022

Status Verified

January 1, 2022

Enrollment Period

3.2 years

First QC Date

October 25, 2019

Last Update Submit

January 24, 2022

Conditions

Keywords

Informed Consent Process

Outcome Measures

Primary Outcomes (1)

  • Number of correctly answered questions between study group and control group

    Patients are asked to complete a multiple choice questionnaire concerning intravitreal drug injections. Correctly answered questions will be summated. The more points the better the patients' knowledge about intravitreal drug injections.

    12 months

Secondary Outcomes (1)

  • Usability of the MacInfo tool

    12 months

Study Arms (2)

MacInfo presentation

ACTIVE COMPARATOR

Patient will get access to an online version of the MacInfo presentation

Other: MacInfo presentation

Placebo presentation

PLACEBO COMPARATOR

Patient will get access to an online version of a placebo presentation

Other: Placebo presentation

Interventions

Presentation about intravitreal drug injection

MacInfo presentation

Placebo presentation

Placebo presentation

Eligibility Criteria

Age21 Years - 105 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 21 or older
  • Patients with a need for intravitreal drug administration: wet, age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal venous occlusion
  • No previous intravitreal injections
  • Willingness and written informed consent to participate in the study

You may not qualify if:

  • Not literate in German
  • Visual acuity of less than 6/60 in the worse eye
  • Severe hearing loss
  • Inability to use a touch screen device (e.g. severe tremor, etc.)
  • Pregnancy - for women in the reproductive age a pregnancy test is required

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Vienna, 1140, Austria

RECRUITING

MeSH Terms

Conditions

Macular DegenerationRetinal Vein Occlusion

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesVenous ThrombosisThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Oliver Findl, MD

    Vienna Institute for Research in Ocular Surgery

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Oliver Findl, MD

CONTACT

Manuel Ruiss, MSc.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 25, 2019

First Posted

October 29, 2019

Study Start

October 24, 2019

Primary Completion

January 1, 2023

Study Completion

January 1, 2024

Last Updated

February 8, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations